Novartis Ag (NVS) 103.45 $NVS
3 Soaring Biotech Stocks Under $10 -- Are They Buys?
Todd Campbell, The Motley Fool - Motley Fool - Wed Apr 22, 9:03AM CDT
There is probably no industry as prone to jaw-dropping pops and drops as biotechnology, so it might not be surprising that these three low-price biotech stocks are racking up remarkable returns so far this year. Although each of these companies has...
CORT: 6.44 (+0.38), NVS: 103.45 (-0.62), EXEL: 3.12 (+0.05), ARRY: 7.25 (-0.10)
Amgen Beats on Q1 Earnings & Revenues, Ups Earnings View - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Apr 22, 8:15AM CDT
Amgen (AMGN) started 2015 on a strong note with earnings and revenues surpassing expectations.
BIIB: 423.57 (+1.46), OSIR: 16.35 (-0.10), AMGN: 169.10 (+0.64), NVS: 103.45 (-0.62)
Novartis Rises 1.79% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Tue Apr 21, 5:24PM CDT
Novartis (NYSE:NVS) traded in a range yesterday that spanned from a low of $103.98 to a high of $104.66. Yesterday, the shares gained 1.8%, which took the trading range above the 3-day high of $103.75 on volume of 1.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
NVS: 103.45 (-0.62)
Will Eli Lilly (LLY) Beat Earnings in 1Q Despite Generics? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 21, 2:12PM CDT
New products and continued growth of a few core products could help Eli Lilly (LLY) beat earnings expectations in 1Q despite generics and currency headwinds.
BIIB: 423.57 (+1.46), IMGN: 9.96 (+0.01), LLY: 72.30 (+0.09), NVS: 103.45 (-0.62)
Juno Therapeutics Gets Lift From Cancer Test Results
at Investor's Business Daily - Tue Apr 21, 1:57PM CDT
Juno Therapeutics' (JUNO) stock rebounded Tuesday as the company reported "highly encouraging" results from a clinical trial on pediatric patients with leukemia, after shares fell sharply Monday. Juno is developing cellular immunotherapies to treat...
BLCM: 28.55 (+2.59), KITE: 57.56 (-1.43), JUNO: 55.72 (-0.68), NVS: 103.45 (-0.62)
Will Novartis' (NVS) Earnings Disappoint This Quarter? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 21, 1:50PM CDT
Switzerland-based Novartis AG (NVS), one of the leading players in the health care solutions, will be reporting its first-quarter 2015 results on Apr 23, 2015.
BIIB: 423.57 (+1.46), IMGN: 9.96 (+0.01), GSK: 46.57 (-0.67), NVS: 103.45 (-0.62)
Novartis celebrates 19th annual Community Partnership Day with more than 27,000 associates volunteering in their local communities
M2 - Tue Apr 21, 10:48AM CDT
- More than 27,000 Novartis associates worldwide dedicate an estimated 200,000 hours to volunteer with charitable causes in their communities
NVS: 103.45 (-0.62)
Teva Bids $40 Billion For Mylan, But May Need More
at Investor's Business Daily - Tue Apr 21, 10:35AM CDT
Israeli drug giant Teva Pharmaceutical Industries (TEVA) made its long-awaited bid for competitor Mylan on Tuesday, offering $82 a share, or $40.1 billion. Both stocks rose on the news. Teva's proposal, half cash and half stock, was unsolicited by...
PRGO: 201.50 (+8.68), MYL: 72.40 (-1.67), TEVA: 63.01 (-1.15), MNTA: 18.62 (+0.56), NVS: 103.45 (-0.62)
Dermatitis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com
PRWeb - Tue Apr 21, 10:31AM CDT
The report "Dermatitis - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic development for Dermatitis. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/dermatitis-p...eport.html .
VTAE: 14.04 (+0.02), FOMX: 10.94 (-0.02), PVCT: 0.90 (unch), JNJ: 100.43 (+0.13), DERM: 15.36 (-0.62), ANAC: 66.45 (-0.22), XNCR: 14.63 (-0.16), REGN: 472.63 (+9.41), AQXP: 7.91 (-0.41), BMY: 66.60 (-0.21), GSK: 46.57 (-0.67), VRX.TO: 253.14 (-6.24), CBPO: 99.67 (-0.84), MRK: 57.69 (+0.03), CCXI: 7.86 (-0.02), CLTX: 0.74 (-0.01), CELGZ: 2.87 (+0.04), NVS: 103.45 (-0.62)
CorTechs Labs Announces Partnership to Provide Comprehensive Solutions for Quantifying Brain Volume Loss in Multiple Sclerosis
PR Newswire Europe - Tue Apr 21, 6:31AM CDT
-- Advanced MS therapeutics combined with the innovative NeuroQuant(R) software provides invaluable information to neurologists and radiologists
NVS: 103.45 (-0.62)
Auto-Injectors Market: Prefilled and Fillable Auto-injectors - Global Industry Analysis 2014 - 2020
M2 - Tue Apr 21, 5:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/25dl9q/autoinjectors) has announced the addition of the "Auto-Injectors Market (Product Types: Prefilled and Fillable Auto-injectors; Therapeutic Applications: Anaphylaxis, Multiple Sclerosis, Rheumatoid Arthritis and Others; Manufacturing Design: Standardized and Customized Auto-injectors) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020" report to their offering. The global auto-injectors market has been segmented on the basis of product, therapeutic applications, and manufacturing design. Based on product type, the global auto-injectors market is classified into two major segments, namely prefilled auto-injectors and fillable auto-injectors. Based on therapeutic applications, the auto-injectors market is differentiated into four segments: anaphylaxis, multiple sclerosis, rheumatoid arthritis, and others. Depending upon the manufacturing design, the global auto-injectors market is categorized into two segments: standardized auto-injectors and customized auto-injectors. Market revenue in terms of USD million for the period between 2012 and 2020 along with the compound annual growth rate (CAGR %) from 2014 to 2020 are provided for all segments, considering 2013 as the base year. This report also includes recommendations that would help new market entrants in establishing presence and existing market players in expanding their global reach and market share in the auto-injectors market. The report concludes by profiling major players in the auto-injectors market. Company overview, financial overview, product portfolio, business strategy, and recent developments are provided for major market players in the company profile section. Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Global Auto-injectors Market Overview Chapter 4 Global Auto-injectors Market, by Product Type Chapter 5 Global Auto-injectors Market, by Manufacturing Design Chapter 6 Global Auto-injectors Market, by Therapeutic Application Chapter 7 Global Auto-injectors Market, by Geography Chapter 8 Recommendations Chapter 9 Company Profiles - Antares Pharma, Inc. - Becton, Dickinson & Company - Biogen Idec - Mylan, Inc. - Novartis International AG - Pfizer, Inc. - Sanofi - Scandinavian Health Ltd (SHL) Group - Unilife Corporation - Ypsomed Holding AG For more information visit http://www.researchandmarkets.com/research/25...oinjectors
BIIB: 423.57 (+1.46), BDX: 144.33 (-1.24), UNIS: 3.79 (-0.12), PFE: 34.93 (+0.04), ATRS: 2.78 (unch), NVS: 103.45 (-0.62)
Data at AAN showed Gilenya(R) high efficacy in achieving 'no evidence of disease activity' in previously-treated highly-active MS patients
Thomson Reuters ONE - Tue Apr 21, 12:15AM CDT
Novartis International AG / Data at AAN showed Gilenya(R) high efficacy in achieving 'no evidence of disease activity' in previously-treated highly-active MS patients . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
NVS: 103.45 (-0.62)
Why Shares of Juno Therapeutics Inc. and Kite Pharma Inc. Crashed Today
Alex Planes, The Motley Fool - Motley Fool - Mon Apr 20, 5:59PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of biotech upstarts Juno Therapeutics and ...
ZIOP: 10.88 (+0.03), KITE: 57.56 (-1.43), JUNO: 55.72 (-0.68), NVS: 103.45 (-0.62)
AACR - Solid Tumour CAR-T Foray Lives Up To Its Low-Key Billing
EP Vantage - at Seeking Alpha - Mon Apr 20, 3:58PM CDT
For some time now solid tumours has been seen as the next big battleground for CAR-T therapy, but based on the underwhelming early data released yesterday at the AACR meeting the best that can be said is that the jury is still out. A very early...
KITE: 57.56 (-1.43), MRK: 57.69 (+0.03), JUNO: 55.72 (-0.68), NVS: 103.45 (-0.62)
Global Amlodipine Besylate Industry 2015-2020 Forecast Analysis Report
PRWeb - Mon Apr 20, 8:31AM CDT
The 2015 Market Research Report on the Global Amlodipine Besylate Industry is a professional and in-depth study on the current state of the global Amlodipine Besylate Market with a focus on the Chinese situation.
NVS: 103.45 (-0.62)
Global Acquired Orphan Blood Diseases Therapeutics Market 2015-2019
M2 - Mon Apr 20, 5:43AM CDT
Research and Markets (http://www.researchandmarkets.com/research/w97ksb/global_acquired) has announced the addition of the "Global Acquired Orphan Blood Diseases Therapeutics Market 2015-2019" report to their offering. The Global Acquired Orphan Blood Diseases Therapeutics market to grow at a CAGR of 12.29% over the period 2014-2019 Acquired orphan blood diseases are rare disorders and are characterized by the body's inability to produce a sufficient amount of RBCs. This is basically because of the improper functioning of bone marrow to produce RBCs in the blood. This leads to a decrease in platelet counts, which can eventually lead to anemia and thrombosis. This report covers the present scenario and the growth prospects of the Global Acquired Orphan Blood Diseases Therapeutics market for the period 2015-2019. To calculate the market size, the report considers revenue generated through the sale of marketed drugs used in the treatment of PNH, ITP, PV, MF, and MDS. Entry into untapped markets is one of the major trends upcoming in the market. Currently, the market in many geographical locations remains untapped and provides immense opportunities for vendors to invest in the same. Companies that are pioneers in the development of drugs for acquired orphan blood diseases target physicians who prescribe patients these drugs instead of surgeries and chemotherapy. This has helped manufacturers to increase their product price. According to the report, patients diagnosed with acquired orphan blood diseases mostly rely on generics for the treatment. Side effects of these drugs are high and the treatment regimen requires high level of commitment from patients such as regular hospital visits and checkups. Further, the report states that most pharmaceutical and biotech companies invest extensively in the development of novel drugs to treat rare diseases. However, when marketing and distribution of drugs to potential consumers is taken into consideration, companies are hesitant to invest for the same. Low prevalence of orphan diseases makes it difficult for companies to locate the target population. Key Vendors - Alexion Pharmaceuticals - Amgen - Celgene - F. Hoffmann- La Roche - GlaxoSmithKline - Incyte Other Prominent Vendors - Cyclacel Pharmaceuticals - CTI Biopharma (Cell Therapeutics) - Eli Lilly - Gilead Sciences - Onconova Therapeutics - MebVax Therapeutics - Novartis - Sanofi - Shire Pharmaceuticals - S* Bio Pte For more information visit http://www.researchandmarkets.com/research/w9...l_acquired
CYCC: 0.94 (-0.03), GILD: 104.18 (-1.02), SHPG: 253.58 (+3.70), ALXN: 188.19 (+1.41), AMGN: 169.10 (+0.64), ONTX: 2.48 (-0.05), LLY: 72.30 (+0.09), GSK: 46.57 (-0.67), NVS: 103.45 (-0.62), CELGZ: 2.87 (+0.04)
Immune Cell Cancer Immunotherapy Passes First Safety Test in Solid Tumors
at The Street - Sun Apr 19, 11:45AM CDT
The positive phase I safety study was conducted using a CAR-T therapy from Novartis and the University of Pennsylvania.
KITE: 57.56 (-1.43), JUNO: 55.72 (-0.68), NVS: 103.45 (-0.62)
3 Megatrends in Healthcare
Sean Williams, The Motley Fool - Motley Fool - Sun Apr 19, 6:14AM CDT
Source: AstraZeneca. For investors, the healthcare sector is where dreams can be made many times over -- or potentially lost in a flash. Although all sectors look to the horizon and think about "what might be," no sector is more reliant on the...
ANTM: 152.84 (-0.04), MYGN: 33.74 (+0.28), MDT: 78.01 (+0.93), PFE: 34.93 (+0.04), CERN: 72.41 (+0.19), NVS: 103.45 (-0.62)
3 Soaring Biotech Stocks Under $10 -- Are They Buys?
Todd Campbell, The Motley Fool - Motley Fool - Wed Apr 22, 9:03AM CDT
There is probably no industry as prone to jaw-dropping pops and drops as biotechnology, so it might not be surprising that these three low-price biotech stocks are racking up remarkable returns so far this year. Although each of these companies has...
CORT: 6.44 (+0.38), NVS: 103.45 (-0.62), EXEL: 3.12 (+0.05), ARRY: 7.25 (-0.10)
Amgen Beats on Q1 Earnings & Revenues, Ups Earnings View - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Apr 22, 8:15AM CDT
Amgen (AMGN) started 2015 on a strong note with earnings and revenues surpassing expectations.
BIIB: 423.57 (+1.46), OSIR: 16.35 (-0.10), AMGN: 169.10 (+0.64), NVS: 103.45 (-0.62)
Novartis Rises 1.79% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Tue Apr 21, 5:24PM CDT
Novartis (NYSE:NVS) traded in a range yesterday that spanned from a low of $103.98 to a high of $104.66. Yesterday, the shares gained 1.8%, which took the trading range above the 3-day high of $103.75 on volume of 1.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
NVS: 103.45 (-0.62)
Will Eli Lilly (LLY) Beat Earnings in 1Q Despite Generics? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 21, 2:12PM CDT
New products and continued growth of a few core products could help Eli Lilly (LLY) beat earnings expectations in 1Q despite generics and currency headwinds.
BIIB: 423.57 (+1.46), IMGN: 9.96 (+0.01), LLY: 72.30 (+0.09), NVS: 103.45 (-0.62)
Juno Therapeutics Gets Lift From Cancer Test Results
at Investor's Business Daily - Tue Apr 21, 1:57PM CDT
Juno Therapeutics' (JUNO) stock rebounded Tuesday as the company reported "highly encouraging" results from a clinical trial on pediatric patients with leukemia, after shares fell sharply Monday. Juno is developing cellular immunotherapies to treat...
BLCM: 28.55 (+2.59), KITE: 57.56 (-1.43), JUNO: 55.72 (-0.68), NVS: 103.45 (-0.62)
Will Novartis' (NVS) Earnings Disappoint This Quarter? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 21, 1:50PM CDT
Switzerland-based Novartis AG (NVS), one of the leading players in the health care solutions, will be reporting its first-quarter 2015 results on Apr 23, 2015.
BIIB: 423.57 (+1.46), IMGN: 9.96 (+0.01), GSK: 46.57 (-0.67), NVS: 103.45 (-0.62)
Novartis celebrates 19th annual Community Partnership Day with more than 27,000 associates volunteering in their local communities
M2 - Tue Apr 21, 10:48AM CDT
- More than 27,000 Novartis associates worldwide dedicate an estimated 200,000 hours to volunteer with charitable causes in their communities
NVS: 103.45 (-0.62)
Teva Bids $40 Billion For Mylan, But May Need More
at Investor's Business Daily - Tue Apr 21, 10:35AM CDT
Israeli drug giant Teva Pharmaceutical Industries (TEVA) made its long-awaited bid for competitor Mylan on Tuesday, offering $82 a share, or $40.1 billion. Both stocks rose on the news. Teva's proposal, half cash and half stock, was unsolicited by...
PRGO: 201.50 (+8.68), MYL: 72.40 (-1.67), TEVA: 63.01 (-1.15), MNTA: 18.62 (+0.56), NVS: 103.45 (-0.62)
Dermatitis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com
PRWeb - Tue Apr 21, 10:31AM CDT
The report "Dermatitis - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic development for Dermatitis. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/dermatitis-p...eport.html .
VTAE: 14.04 (+0.02), FOMX: 10.94 (-0.02), PVCT: 0.90 (unch), JNJ: 100.43 (+0.13), DERM: 15.36 (-0.62), ANAC: 66.45 (-0.22), XNCR: 14.63 (-0.16), REGN: 472.63 (+9.41), AQXP: 7.91 (-0.41), BMY: 66.60 (-0.21), GSK: 46.57 (-0.67), VRX.TO: 253.14 (-6.24), CBPO: 99.67 (-0.84), MRK: 57.69 (+0.03), CCXI: 7.86 (-0.02), CLTX: 0.74 (-0.01), CELGZ: 2.87 (+0.04), NVS: 103.45 (-0.62)
CorTechs Labs Announces Partnership to Provide Comprehensive Solutions for Quantifying Brain Volume Loss in Multiple Sclerosis
PR Newswire Europe - Tue Apr 21, 6:31AM CDT
-- Advanced MS therapeutics combined with the innovative NeuroQuant(R) software provides invaluable information to neurologists and radiologists
NVS: 103.45 (-0.62)
Auto-Injectors Market: Prefilled and Fillable Auto-injectors - Global Industry Analysis 2014 - 2020
M2 - Tue Apr 21, 5:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/25dl9q/autoinjectors) has announced the addition of the "Auto-Injectors Market (Product Types: Prefilled and Fillable Auto-injectors; Therapeutic Applications: Anaphylaxis, Multiple Sclerosis, Rheumatoid Arthritis and Others; Manufacturing Design: Standardized and Customized Auto-injectors) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020" report to their offering. The global auto-injectors market has been segmented on the basis of product, therapeutic applications, and manufacturing design. Based on product type, the global auto-injectors market is classified into two major segments, namely prefilled auto-injectors and fillable auto-injectors. Based on therapeutic applications, the auto-injectors market is differentiated into four segments: anaphylaxis, multiple sclerosis, rheumatoid arthritis, and others. Depending upon the manufacturing design, the global auto-injectors market is categorized into two segments: standardized auto-injectors and customized auto-injectors. Market revenue in terms of USD million for the period between 2012 and 2020 along with the compound annual growth rate (CAGR %) from 2014 to 2020 are provided for all segments, considering 2013 as the base year. This report also includes recommendations that would help new market entrants in establishing presence and existing market players in expanding their global reach and market share in the auto-injectors market. The report concludes by profiling major players in the auto-injectors market. Company overview, financial overview, product portfolio, business strategy, and recent developments are provided for major market players in the company profile section. Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Global Auto-injectors Market Overview Chapter 4 Global Auto-injectors Market, by Product Type Chapter 5 Global Auto-injectors Market, by Manufacturing Design Chapter 6 Global Auto-injectors Market, by Therapeutic Application Chapter 7 Global Auto-injectors Market, by Geography Chapter 8 Recommendations Chapter 9 Company Profiles - Antares Pharma, Inc. - Becton, Dickinson & Company - Biogen Idec - Mylan, Inc. - Novartis International AG - Pfizer, Inc. - Sanofi - Scandinavian Health Ltd (SHL) Group - Unilife Corporation - Ypsomed Holding AG For more information visit http://www.researchandmarkets.com/research/25...oinjectors
BIIB: 423.57 (+1.46), BDX: 144.33 (-1.24), UNIS: 3.79 (-0.12), PFE: 34.93 (+0.04), ATRS: 2.78 (unch), NVS: 103.45 (-0.62)
Data at AAN showed Gilenya(R) high efficacy in achieving 'no evidence of disease activity' in previously-treated highly-active MS patients
Thomson Reuters ONE - Tue Apr 21, 12:15AM CDT
Novartis International AG / Data at AAN showed Gilenya(R) high efficacy in achieving 'no evidence of disease activity' in previously-treated highly-active MS patients . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
NVS: 103.45 (-0.62)
Why Shares of Juno Therapeutics Inc. and Kite Pharma Inc. Crashed Today
Alex Planes, The Motley Fool - Motley Fool - Mon Apr 20, 5:59PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of biotech upstarts Juno Therapeutics and ...
ZIOP: 10.88 (+0.03), KITE: 57.56 (-1.43), JUNO: 55.72 (-0.68), NVS: 103.45 (-0.62)
AACR - Solid Tumour CAR-T Foray Lives Up To Its Low-Key Billing
EP Vantage - at Seeking Alpha - Mon Apr 20, 3:58PM CDT
For some time now solid tumours has been seen as the next big battleground for CAR-T therapy, but based on the underwhelming early data released yesterday at the AACR meeting the best that can be said is that the jury is still out. A very early...
KITE: 57.56 (-1.43), MRK: 57.69 (+0.03), JUNO: 55.72 (-0.68), NVS: 103.45 (-0.62)
Global Amlodipine Besylate Industry 2015-2020 Forecast Analysis Report
PRWeb - Mon Apr 20, 8:31AM CDT
The 2015 Market Research Report on the Global Amlodipine Besylate Industry is a professional and in-depth study on the current state of the global Amlodipine Besylate Market with a focus on the Chinese situation.
NVS: 103.45 (-0.62)
Global Acquired Orphan Blood Diseases Therapeutics Market 2015-2019
M2 - Mon Apr 20, 5:43AM CDT
Research and Markets (http://www.researchandmarkets.com/research/w97ksb/global_acquired) has announced the addition of the "Global Acquired Orphan Blood Diseases Therapeutics Market 2015-2019" report to their offering. The Global Acquired Orphan Blood Diseases Therapeutics market to grow at a CAGR of 12.29% over the period 2014-2019 Acquired orphan blood diseases are rare disorders and are characterized by the body's inability to produce a sufficient amount of RBCs. This is basically because of the improper functioning of bone marrow to produce RBCs in the blood. This leads to a decrease in platelet counts, which can eventually lead to anemia and thrombosis. This report covers the present scenario and the growth prospects of the Global Acquired Orphan Blood Diseases Therapeutics market for the period 2015-2019. To calculate the market size, the report considers revenue generated through the sale of marketed drugs used in the treatment of PNH, ITP, PV, MF, and MDS. Entry into untapped markets is one of the major trends upcoming in the market. Currently, the market in many geographical locations remains untapped and provides immense opportunities for vendors to invest in the same. Companies that are pioneers in the development of drugs for acquired orphan blood diseases target physicians who prescribe patients these drugs instead of surgeries and chemotherapy. This has helped manufacturers to increase their product price. According to the report, patients diagnosed with acquired orphan blood diseases mostly rely on generics for the treatment. Side effects of these drugs are high and the treatment regimen requires high level of commitment from patients such as regular hospital visits and checkups. Further, the report states that most pharmaceutical and biotech companies invest extensively in the development of novel drugs to treat rare diseases. However, when marketing and distribution of drugs to potential consumers is taken into consideration, companies are hesitant to invest for the same. Low prevalence of orphan diseases makes it difficult for companies to locate the target population. Key Vendors - Alexion Pharmaceuticals - Amgen - Celgene - F. Hoffmann- La Roche - GlaxoSmithKline - Incyte Other Prominent Vendors - Cyclacel Pharmaceuticals - CTI Biopharma (Cell Therapeutics) - Eli Lilly - Gilead Sciences - Onconova Therapeutics - MebVax Therapeutics - Novartis - Sanofi - Shire Pharmaceuticals - S* Bio Pte For more information visit http://www.researchandmarkets.com/research/w9...l_acquired
CYCC: 0.94 (-0.03), GILD: 104.18 (-1.02), SHPG: 253.58 (+3.70), ALXN: 188.19 (+1.41), AMGN: 169.10 (+0.64), ONTX: 2.48 (-0.05), LLY: 72.30 (+0.09), GSK: 46.57 (-0.67), NVS: 103.45 (-0.62), CELGZ: 2.87 (+0.04)
Immune Cell Cancer Immunotherapy Passes First Safety Test in Solid Tumors
at The Street - Sun Apr 19, 11:45AM CDT
The positive phase I safety study was conducted using a CAR-T therapy from Novartis and the University of Pennsylvania.
KITE: 57.56 (-1.43), JUNO: 55.72 (-0.68), NVS: 103.45 (-0.62)
3 Megatrends in Healthcare
Sean Williams, The Motley Fool - Motley Fool - Sun Apr 19, 6:14AM CDT
Source: AstraZeneca. For investors, the healthcare sector is where dreams can be made many times over -- or potentially lost in a flash. Although all sectors look to the horizon and think about "what might be," no sector is more reliant on the...
ANTM: 152.84 (-0.04), MYGN: 33.74 (+0.28), MDT: 78.01 (+0.93), PFE: 34.93 (+0.04), CERN: 72.41 (+0.19), NVS: 103.45 (-0.62)
